Clinical trials: Haemophilus Influenzae
Pertussis Immunisation, Diphtheria Immunisation
Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand
Primary Objective: To demonstrate the non-inferiority of the SHAN6™ vaccine to the licensed SHAN5™ given with bOPV and IPV vaccines when coadministered with PCV and ORV Secondary Objective: To describe the immunogenicity profile…
- Conditions
- Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation, Hepatitis B Immunisation
- Trial name
- NCT04429295
- Testing
- DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus), DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b), Inactivated Poliomyelitis Vaccine
- Where
- 3 sites in Thailand
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
To demonstrate that DTaP-IPV-HB-PRP~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the three vaccinations at 2, 4, and 6 months of age…
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00313911
- Testing
- DTaP-IPV-HB-PRP~T, Tritanrix-HepB/Hib
- Where
- 2 sites in Mexico, Peru
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acellular Pertussis, Tetanus
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
Booster and immune memory study
- Conditions
- Acellular Pertussis, Tetanus, Hepatitis B, Diphtheria
- Trial name
- NCT00307567
- Testing
- Pneumococcal (vaccine)
- Where
- 51 sites in Germany
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
The purpose of this study is to support the registration of the pentavalent DTaP-HB-PRP~T vaccine in countries that follow the World Health Organization-Expanded Program of Immunization (WHO-EPI) schedule.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00343889
- Testing
- DTaP-HB-PRP~T vaccine + OPV, Tritanrix-HepB/Hib™ + OPV vaccine, Oral Polio Vaccine
- Where
- 2 sites in Philippines
- Volunteers
- 379 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acellular Pertussis, Diphtheria
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine
The purpose of this booster study is to evaluate, in subjects primed in the primary study 106786, the persistence, at the time of the booster vaccination, of antibodies elicited by the different formulation of DTPa-HBV-IPV/ Hib…
- Conditions
- Acellular Pertussis, Diphtheria, Poliomyelitis, Haemophilus Influenzae Type b
- Trial name
- NCT00627458
- Testing
- Infanrix Hexa
- Where
- 6 sites in Finland
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Diphtheria
A Phase IV Study to Assess the Safety of EupentaTM Inj
A prospective, open-label, interventional phase IV study to assess the safety of EupentaTM Inj.{fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [recombinant-deoxyribonucleic…
- Conditions
- Hepatitis B, Diphtheria, Haemophilus Influenzae Type B Infection, Tetanus
- Trial name
- NCT04056728
- Testing
- Eupenta Inj.
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diphtheria, Tetanus
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age
This study will evaluate immunogenicity, safety and tolerability of fully liquid pentavalent vaccine (DTwP-Hib-HepB Vaccine) in infants 6-8 weeks of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT01470287
- Testing
- DTwP-HepB-Hib Vaccine
- Where
- 3 sites in India
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Haemophilus Influenzae Type b, Neisseria Meningitidis
Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
This study evaluated the safety and immunogenicity of 3 formulations of Hib-MenCY-TT vaccine compared to 2 control groups receiving licensed meningococcal serogroup C conjugate vaccine and/or licensed Hib conjugate vaccine…
- Trial name
- NCT00127855
- Testing
- Hib-MenCY-TT vaccine (MenHibrix), Meningitec®, ActHIB®
- Where
- 3 sites in Australia
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Haemophilus Influenzae Type b, Neisseria Meningitidis
Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC
This protocol posting deals with objectives \& outcome measures of the extension phase at Months 18, 30, 42, 54 and 66 post booster.
- Trial name
- NCT00322335
- Testing
- Haemophilus influenzae type b- and meningococcal (vaccine), Infanrix™ penta, Infanrix™ hexa
- Where
- 12 sites in Spain
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Immunisation, Diphtheria Immunisation
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Primary objectives: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation
- Trial name
- NCT04398706
- Testing
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3
- Where
- 57 sites in United States, Canada and 2 more
- Volunteers
- 852 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Haemophilus Influenzae, Haemophilus Influenzae Type a
Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine
This study is testing a vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections.This is a phase 2 trial.
- Trial name
- NCT07743008
- Testing
- Haemophilus influenzae serotype a vaccine candidate
- Where
- 2 sites in Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- InventVacc Biologicals Inc.
Healthy
A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule
The purpose of this study is to assess the safety and reactogenicity of 3 different dose levels of inactivated poliovirus vaccine based on Sabin strains (sIPV) in healthy participants, using conventional Salk IPV (cIPV) as an…
- Trial name
- NCT03566940
- Testing
- sIPV, cIPV
- Where
- 3 sites in Philippines
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Haemophilus Infections, Diphtheria
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
To monitor the occurrence of invasive Hib disease over time and to determine product-specific rates of invasive Hib disease within the monitored population.
- Conditions
- Haemophilus Infections, Diphtheria, Tetanus, Polio
- Trial name
- NCT00855855
- Testing
- DTaP-IPV/Hib
- Where
- 59 sites in United States
- Volunteers
- 20,830 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Streptococcus Pneumoniae, Neisseria Meningitidis
Neisseria Meningitidis Burden of Disease Study
This study aims to provide an estimate of the proportion of suspected cases of bacterial meningitis that are due to N. meningitidis and the serogroup responsible in The Philippines and Vietnam.
- Conditions
- Streptococcus Pneumoniae, Neisseria Meningitidis, Haemophilus Influenzae
- Trial name
- NCT01730391
- Testing
- Data collection, CSF samples testing
- Where
- 3 sites in Philippines, Vietnam
- Volunteers
- 521 people
- Sponsor
- GlaxoSmithKline
Haemophilus Influenzae Type b
Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™
In order to reduce the amount of thiomersal in its vaccines, GSK Biologicals has developed a DTPw-HBV vaccine with low thiomersal content (Tritanrix™- HepB low thio).
- Trial name
- NCT01061541
- Testing
- Tritanrix™-HepB low thio /, Hib 2.5, Tritanrix™-HepB
- Where
- Philippines
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Otitis Media
Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Taiwan
The purpose of the study is to identify the bacterial aetiology of Acute Otitis Media episodes in young children aged >= 3 months to < 5 years in Taiwan
- Trial name
- NCT01072227
- Testing
- Sample Collection
- Where
- 2 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Haemophilus Influenzae Type b (Hib) Infection
Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants
This study will evaluate the safety and immunogenicity of booster dose of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 365-569 days of age
- Trial name
- NCT01226953
- Testing
- Haemophilus influenzae type b (Hib) vaccine
- Where
- China
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Infectious Disease by Haemophilus Influenzae Type b
Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age
The purpose of this study is to evaluate and compare the immunogenicity and safety of LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) to that of Hiberix™ at vaccination in healthy infants at their 2, 4…
- Trial name
- NCT01019772
- Testing
- LBVH0101 (Hib vaccine), Hiberix™ Vaccine
- Where
- South Korea
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Diphtheria, Hepatitis B
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 11-18 months of age to infants who received primary vaccination at 6-14 weeks.
- Conditions
- Diphtheria, Hepatitis B, Acellular Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT02853929
- Testing
- Infanrix hexa
- Where
- 29 sites in Australia, Canada and 4 more
- Volunteers
- 551 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Haemophilus Influenzae Type b, Diphtheria
Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants
The purpose of this study is to compare the immune response, safety and reactogenicity of Tritanrix™-HepB/Hib-MenAC vaccine given either with or without a birth dose of hepatitis B vaccine to Tritanrix™-HepB/Hiberix™ when given…
- Conditions
- Haemophilus Influenzae Type b, Diphtheria, Whole Cell Pertussis, Hepatitis B
- Trial name
- NCT00290303
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- 3 sites in Philippines
- Volunteers
- 996 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline